FRAX597, a PAK1 inhibitor, synergistically reduces pancreatic cancer growth when combined with gemcitabine

BACKGROUND: Pancreatic ductal adenocarcinoma remains one of the most lethal of all solid tumours. Treatment options are limited and gemcitabine-based chemotherapy remains the standard of care. Although growing evidence shows that p21-activated kinase 1 (PAK1) plays a crucial role in pancreatic cance...

Descripción completa

Detalles Bibliográficos
Autores principales: Yeo, Dannel, He, Hong, Patel, Oneel, Lowy, Andrew M., Baldwin, Graham S., Nikfarjam, Mehrdad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4715347/
https://www.ncbi.nlm.nih.gov/pubmed/26774265
http://dx.doi.org/10.1186/s12885-016-2057-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4715347/
https://www.ncbi.nlm.nih.gov/pubmed/26774265
http://dx.doi.org/10.1186/s12885-016-2057-z

Ejemplares similares